[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637503":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":10,"locations":23,"responsibleParty":43,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Sichuan Provincial People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sulbactam-Durlobactam Group",null,"Patients receiving sulbactam-durlobactam within 48 hours after treatment initiation.",[13],"Drug: Sulbactam-Durlobactam",{"label":15,"type":10,"description":16,"interventionNames":10},"Non-Sulbactam-Durlobactam Group","Patients receiving alternative anti-CRAB regimens during the same period without sulbactam-durlobactam.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Sulbactam-Durlobactam","Sulbactam-durlobactam administered according to routine clinical practice for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infection.",[9],[24],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Chengdu","Sichuan","610072","China","CN",{"type":32,"coordinates":33},"Point",[34,35],104.06667,30.66667,{"lat":35,"lon":34},[38],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Lingai Pan, MD","CONTACT","+86 17708130236","panlingai2004@163.com",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Lingai Pan","Associate Chief Physician, Department of Critical Care Medicine","100637503","sulbactam-durlobactam-in-crab-infection-a-real-world-cohort-study-100637503",false,"NCT07601711","Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study","This is a Single-center Real-world Observational Cohort Study of Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter Baumannii Infections: Effectiveness, Safety, and Exposure-Response Analysis","SD-CRAB","Inclusion Criteria:\n\n* Age ≥18 years.\n* Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:\n\n  1. patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or\n  2. transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy.\n* Treatment initiation time can be clearly determined.\n* Availability of clinical outcome data.\n\nExclusion Criteria:\n\n* Colonization without evidence of active infection.\n* Missing key clinical data.\n* Inability to determine treatment initiation time.\n* Pregnancy or lactation.\n* Patients considered unsuitable by investigators.","ALL","18 Years",{"count":58,"type":59},200,"ESTIMATED","OBSERVATIONAL","This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.\n\nThe primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.\n\nTo reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.",[63,64,65,66],"Carbapenem-Resistant Acinetobacter Baumannii Infection","Bloodstream Infection","Pneumonia","Sepsis",[68],"CRAB Infection","2026-05-19",{"date":71,"type":72},"2026-05-22","ACTUAL",{"date":74,"type":72},"2025-11-11",{"date":76,"type":59},"2027-11-11",{"name":5,"class":6},1]